DalsnaFinance

Bristol Myers Squibb $BMY

Health Care · Pharmaceuticals · NYSE/NASDAQ

S&P 500 Russell 1000 New Jersey
Create a scorecard
$61.48
+2.65 (+4.50%)
As of Oct 20, 2026, 12:59 PM EDT
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 13, 2026, the first target we tracked for BMY.

Key facts

52-week range (closes)
$42.60 – $68.09 Lowest close Oct 29, 2025, highest Sep 3, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings
Oct 29, 2026, before the open · EPS forecast $1.28 Nasdaq earnings calendar, as of Oct 20, 2026
Fiscal year ends
December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since
Mar 4, 1957 · All S&P 500 changes
Analyst coverage
1 open price target from 1 firm: Wells Fargo Approved targets tracked here; see the analyst section below

Bristol Myers Squibb (BMY) is trading up at $61.48 (+4.50%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on BMY

One firm's current price target on Bristol Myers Squibb: $60 — 2% below the current $61.5. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Bristol Myers Squibb revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$48.3B$19.6B−$9.02BFY2016 revenue: $19.4BFY2016 net income: $4.46B · Net margin 22.9%'16FY2017 revenue: $20.8BFY2017 net income: $1.01B · Net margin 4.8%'17FY2018 revenue: $22.6BFY2018 net income: $4.92B · Net margin 21.8%'18FY2019 revenue: $26.1BFY2019 net income: $3.44B · Net margin 13.2%'19FY2020 revenue: $42.5BFY2020 net income: −$9.02B · Net margin −21.2%'20FY2021 revenue: $46.4BFY2021 net income: $6.99B · Net margin 15.1%'21FY2022 revenue: $46.2BFY2022 net income: $6.33B · Net margin 13.7%'22FY2023 revenue: $45.0BFY2023 net income: $8.03B · Net margin 17.8%'23FY2024 revenue: $48.3BFY2024 net income: −$8.95B · Net margin −18.5%'24FY2025 revenue: $48.2BFY2025 net income: $7.05B · Net margin 14.6%'25−11.2%0%20%40%60%FY2016 net margin: 22.9%FY2017 net margin: 4.8%FY2018 net margin: 21.8%FY2019 net margin: 13.2%FY2020 net margin: −21.2% (off the scale, which stops at −11.2%)FY2021 net margin: 15.1%FY2022 net margin: 13.7%FY2023 net margin: 17.8%FY2024 net margin: −18.5% (off the scale, which stops at −11.2%)FY2025 net margin: 14.6%
Bristol Myers Squibb annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$19.4B$20.8B$22.6B$26.1B$42.5B$46.4B$46.2B$45.0B$48.3B$48.2B
Growth (year over year)+17.3%+6.9%+8.6%+15.9%+62.6%+9.1%−0.5%−2.5%+7.3%−0.2%
Gross profit$14.5B$14.7B$16.1B$18.1B$30.7B$36.4B$36.0B$34.3B$34.3B$34.3B
Gross margin74.5%70.7%71.3%69.1%72.3%78.6%78.0%76.2%71.1%71.1%
Net income$4.46B$1.01B$4.92B$3.44B−$9.02B$6.99B$6.33B$8.03B−$8.95B$7.05B
Net margin22.9%4.8%21.8%13.2%−21.2%15.1%13.7%17.8%−18.5%14.6%
EPS (diluted)$2.65$0.61$3.01$2.01−$3.99$3.12$2.95$3.86−$4.41$3.46
Balance sheet
Cash and equivalents$4.24B$5.42B$6.91B$12.3B$14.5B$14.0B$9.12B$11.5B$10.3B$10.2B
Total assets$33.7B$33.6B$35.0B$129.9B$118.5B$109.3B$96.8B$95.2B$92.6B$90.0B
Total liabilities$17.4B$21.7B$20.9B$78.2B$80.6B$73.3B$65.7B$65.7B$76.2B$71.5B
Long-term debt$5.72B$6.97B$5.65B$43.4B$48.3B$39.6B$35.1B$36.7B$47.6B$42.9B
Shareholders' equity$16.2B$11.7B$14.0B$51.6B$37.8B$35.9B$31.1B$29.4B$16.3B$18.5B
Cash flow
Operating cash flow$3.06B$5.28B$7.07B$8.21B$14.1B$16.2B$13.1B$13.9B$15.2B$14.2B
Capital expenditure$1.22B$1.05B$951.0M$836.0M$753.0M$973.0M$1.12B$1.21B$1.25B$1.31B
Free cash flow$1.84B$4.22B$6.12B$7.37B$13.3B$15.2B$11.9B$12.7B$13.9B$12.8B
Dividends paid$2.55B$2.58B$2.61B$2.68B$4.08B$4.40B$4.63B$4.74B$4.86B$5.04B
Share buybacks$231.0M$2.47B$320.0M$7.30B$1.55B$6.29B$8.00B$5.16B$0$0

From Bristol Myers Squibb's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Bristol Myers Squibb vs the Health Care sector and the S&P 500

Bristol Myers Squibb's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Bristol Myers Squibb compared with the median Health Care company and the median S&P 500 company
MeasureBristol Myers SquibbHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year−0.2%+7.2%+7.0%
Net margin, latest fiscal year14.6%12.9%12.9%
Dividend per share, latest fiscal year$2.49$2.43$2.40
Share price change, 1 year+35.0%+19.8%+5.6%

Bristol Myers Squibb: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Bristol Myers Squibb included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Bristol Myers Squibb

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.

Source: Wikipedia — Bristol Myers Squibb

Headquarters
Princeton, New Jersey From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →